Emerging ECG-Based AI Screening Software for Aortic Valve Stenosis Gets FDA’s Breakthrough Device Designation
With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.
The Food and Drug Administration (FDA) has issued its Breakthrough Device Designation for screening software that utilizes artificial intelligence (AI) assessment of existing electrocardiograms (ECGs) to identify patients who may have aortic valve stenosis (AVS).1
Estimated one-year mortality rates can be as high as 50 percent for undetected AVS, according to AccurKardia, the developer of the software.2 However, the company noted the AVS screening software is able to identify patients at risk of AVS through a review of existing ECGs in a patient’s electronic health record. The screening software subsequently flags patients for a follow-up ECG to confirm the AVS diagnosis, according to AccurKardia.
“AccurKardia’s recent advancement has the potential to create a paradigm shift in the detection of aortic valve stenosis, where earlier detection and treatment may mean the difference between life or death,” said Eduardo Hernandez, M.D., president of the Texas Heart Institute Center for Cardiovascular Care in Houston. “Once FDA-cleared and successfully deployed, this technology could become established as a standard-of-care screening tool for AVS in elderly patients.”
Through earlier detection and intervention for AVS, AccurKardia suggests the AI-powered screening software could also reduce heart failure hospitalizations and potentially save millions in health-care costs.
References
1. AccurKardia. AccurKardia receives FDA breakthrough device designation for first-of-its-kind aortic valve stenosis ECG-based AI screening software. Available at: https://www.businesswire.com/news/home/20241008099886/en/AccurKardia-Receives-FDA-Breakthrough-Device-Designation-for-First-of-its-Kind-Aortic-Valve-Stenosis-ECG-based-AI-Screening-Software . Published October 8, 2024. Accessed October 8, 2024.
2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.
Recent Videos
Related Content
FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
April 8th 2025Article
For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Article
Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
